MCID: NNL002
MIFTS: 56

Nonalcoholic Steatohepatitis

Categories: Rare diseases, Liver diseases

Aliases & Classifications for Nonalcoholic Steatohepatitis

MalaCards integrated aliases for Nonalcoholic Steatohepatitis:

Name: Nonalcoholic Steatohepatitis 49 24 69
Non-Alcoholic Fatty Liver Disease 49 24 69
Nonalcoholic Fatty Liver Disease 24 36
Non-Alcoholic Steatohepatitis 49 24
Fatty Liver 24 69
Nash 49 24
Fatty Degeneration 69
Steatohepatitis 69
Steatosis 24
Nafld 24

Classifications:



External Ids:

KEGG 36 H01333

Summaries for Nonalcoholic Steatohepatitis

NIH Rare Diseases : 49 Nonalcoholic steatohepatitis, or NASH, is a common, often “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear. Last updated: 2/24/2012

MalaCards based summary : Nonalcoholic Steatohepatitis, also known as non-alcoholic fatty liver disease, is related to hepatitis and lipodystrophy, familial partial, type 2. An important gene associated with Nonalcoholic Steatohepatitis is NAFLD2 (Fatty Liver Disease, Nonalcoholic, Susceptibility To, 2), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Rosiglitazone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

Genetics Home Reference : 24 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

Wikipedia : 72 Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which occurs when fat is... more...

Related Diseases for Nonalcoholic Steatohepatitis

Diseases related to Nonalcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.2 F2 GPT SLC17A5 TNF
2 lipodystrophy, familial partial, type 2 30.4 INS LEP
3 lipodystrophy 30.4 ADIPOQ INS LEP
4 acanthosis nigricans 30.3 ADIPOQ INS LEP
5 morbid obesity 30.2 ADIPOQ INS LEP RETN
6 cryptogenic cirrhosis 30.1 F2 HFE KRT18
7 apnea, obstructive sleep 30.0 ADIPOQ IL6 INS LEP TNF
8 sleep apnea 30.0 ADIPOQ IL6 INS LEP TNF
9 portal hypertension 30.0 F2 GPT TNF
10 hepatitis b 30.0 F2 GPT SLC17A5 TNF
11 chronic kidney failure 29.9 IL6 INS LEP
12 alcoholic liver cirrhosis 29.6 F2 PNPLA3 SLC17A5 TNF
13 alcoholic hepatitis 29.6 F2 GPT IL6 KRT18 SLC17A5 TNF
14 fatty liver disease 29.6 ADIPOQ GPT HFE IL6 INS KRT18
15 diabetes mellitus 29.3 ADIPOQ HFE IL6 INS LEP TNF
16 viral hepatitis 29.1 F2 GPT HFE KRT18 SLC17A5 TNF
17 liver cirrhosis 29.1 ADIPOQ F2 GPT HFE KRT18 SLC17A5
18 body mass index quantitative trait locus 11 29.0 ADIPOQ GPT IL6 INS LEP PNPLA3
19 liver disease 28.0 ADIPOQ F2 GPT HFE IL6 INS
20 visceral steatosis 12.1
21 visceral steatosis, congenital 11.9
22 fibrosis of extraocular muscles, congenital, 1 10.7
23 body mass index quantitative trait locus 12 10.7
24 body mass index quantitative trait locus 14 10.7
25 body mass index quantitative trait locus 9 10.7
26 body mass index quantitative trait locus 18 10.7
27 body mass index quantitative trait locus 8 10.7
28 body mass index quantitative trait locus 7 10.7
29 body mass index quantitative trait locus 4 10.7
30 body mass index quantitative trait locus 10 10.7
31 paraquat poisoning 10.5 GPT SLC17A5
32 hepatocellular carcinoma 10.5
33 pyridoxine deficiency 10.5 GPT SLC17A5
34 hepatitis c 10.4
35 scorpion envenomation 10.4 IL6 TNF
36 fascioliasis 10.4 GPT INS SLC17A5
37 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.4 INS LEP
38 adult dermatomyositis 10.4 GPT TNF
39 abdominal obesity-metabolic syndrome 1 10.4 ADIPOQ INS LEP
40 scrub typhus 10.4 GPT SLC17A5 TNF
41 nontuberculous mycobacterial lung disease 10.4 ADIPOQ LEP TNF
42 choline deficiency disease 10.4
43 endocrine pancreas disease 10.4 ADIPOQ INS LEP
44 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
45 malignant otitis externa 10.4 F2 INS
46 burns 10.4 INS TNF
47 critical limb ischemia 10.4 IL6 TNF
48 streptococcal toxic-shock syndrome 10.3 IL6 TNF
49 aging 10.3
50 hepatoportal sclerosis 10.3 F2 GPT

Graphical network of the top 20 diseases related to Nonalcoholic Steatohepatitis:



Diseases related to Nonalcoholic Steatohepatitis

Symptoms & Phenotypes for Nonalcoholic Steatohepatitis

MGI Mouse Phenotypes related to Nonalcoholic Steatohepatitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.15 TNF RETN SLC17A5 SQSTM1 LEP HFE
2 growth/size/body region MP:0005378 10.14 TNF SLC17A5 SQSTM1 LEP HFE PPARA
3 adipose tissue MP:0005375 10.03 TNF RETN SQSTM1 PPARA IL6 INS
4 immune system MP:0005387 10.02 TNF RETN SQSTM1 LEP HFE PPARA
5 integument MP:0010771 9.86 TNF SQSTM1 LEP PPARA IL6 INS
6 liver/biliary system MP:0005370 9.85 TNF SQSTM1 HFE PPARA IL6 RETN
7 mortality/aging MP:0010768 9.7 SQSTM1 TNF SLC17A5 F2 LEP HFE
8 skeleton MP:0005390 9.23 SQSTM1 TNF F2 GPT LEP IL6

Drugs & Therapeutics for Nonalcoholic Steatohepatitis

Drugs for Nonalcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 4,Phase 2 122320-73-4 77999
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
4
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051 23994
5
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
6
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 4091 14219
7
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
8
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
9
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
10
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
11
Amlodipine Approved Phase 4 88150-42-9 2162
12
Ribavirin Approved Phase 4 36791-04-5 37542
13
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
14
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
15
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
16
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
17
Rifampin Approved Phase 4,Phase 1 13292-46-1 5381226 5458213
18
Gliclazide Approved Phase 4 21187-98-4 3475
19
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
20
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
21
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
22
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
23
Empagliflozin Approved Phase 4,Not Applicable 864070-44-0
24
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
25
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3 80621-81-4 6436173
26
Insulin Aspart Approved Phase 4 116094-23-6 16132418
27
Insulin Detemir Approved Phase 4 169148-63-4 5311023
28
Glimepiride Approved Phase 4 93479-97-1 3476
29
Saxagliptin Approved Phase 4 361442-04-8 11243969
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
31 Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-14-6 5280793
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-02-9 14985
34 tannic acid Approved, Nutraceutical Phase 4,Phase 3
35
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 10883523 5280795 6221
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
37
Ginseng Approved, Investigational, Nutraceutical Phase 4,Not Applicable 50647-08-0
38
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
39
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3 66-72-8 1050
40
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
41 insulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Atorvastatin Calcium Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-03-8
43 interferons Phase 4,Not Applicable
44 calcium channel blockers Phase 4
45 diuretics Phase 4,Phase 2,Phase 3
46
protease inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
47 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
48 Sodium Chloride Symporter Inhibitors Phase 4
49 Natriuretic Agents Phase 4,Phase 2
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 626)

# Name Status NCT ID Phase Drugs
1 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
3 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
7 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
8 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
9 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
10 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
11 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
12 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
13 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
14 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
15 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
16 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
17 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
18 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
19 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
20 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
21 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
22 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
23 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
24 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
25 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
26 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
27 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
28 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
29 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
30 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
31 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
32 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4 Metadoxine
33 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
34 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Recruiting NCT02637973 Phase 4 Empagliflozin;Placebo
35 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
36 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Enrolling by invitation NCT02210715 Phase 4 Isentress.
37 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Enrolling by invitation NCT03222206 Phase 4 Salsalate
38 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Not yet recruiting NCT03198572 Phase 4 Placebo;Berberine
39 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Not yet recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
40 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4 Silymarin
41 High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes Not yet recruiting NCT03403556 Phase 4 Rosuvamibe;Monorova
42 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
43 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
44 Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
45 Fatty Liver Study in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
46 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
47 Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI Withdrawn NCT02263677 Phase 4 Sitagliptin
48 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
49 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
50 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3

Search NIH Clinical Center for Nonalcoholic Steatohepatitis

Genetic Tests for Nonalcoholic Steatohepatitis

Anatomical Context for Nonalcoholic Steatohepatitis

MalaCards organs/tissues related to Nonalcoholic Steatohepatitis:

38
Liver, Testes, Heart, Spleen, Endothelial, Bone, Kidney

Publications for Nonalcoholic Steatohepatitis

Articles related to Nonalcoholic Steatohepatitis:

(show top 50) (show all 810)
# Title Authors Year
1
Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis. ( 29128353 )
2018
2
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. ( 29367468 )
2018
3
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. ( 29406435 )
2018
4
Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. ( 29381754 )
2018
5
Organic Solute Transporter OSTI+/A9 is Over-Expressed in Nonalcoholic Steatohepatitis and Modulated by Drugs Associated with Liver Injury. ( 29420067 )
2018
6
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. ( 29291351 )
2018
7
A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. ( 29311502 )
2018
8
Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. ( 29404772 )
2018
9
Metabolic Syndrome is Associated with Health-Related Quality of Life in Suspected Patients with Nonalcoholic Steatohepatitis. ( 29402822 )
2018
10
Haptoglobin Genotype and VitaminA E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. ( 29411270 )
2018
11
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. ( 29375204 )
2018
12
Relationship between intestinal flora and inflammatory factors in patients with nonalcoholic steatohepatitis. ( 29399077 )
2018
13
Mouse Models Of Nonalcoholic Steatohepatitis: A Reflection On Recent Literature. ( 29424123 )
2018
14
Dual regulation of HMGB1 by combined JNK1/2-ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice. ( 29298863 )
2018
15
Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. ( 29299759 )
2018
16
Nonalcoholic steatohepatitis: the new frontier for liver transplantation. ( 29356708 )
2018
17
Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. ( 29341352 )
2018
18
Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. ( 29401710 )
2018
19
Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. ( 28218919 )
2017
20
Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. ( 28472039 )
2017
21
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. ( 28845983 )
2017
22
Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. ( 27995687 )
2017
23
Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. ( 28823616 )
2017
24
Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis. ( 28912806 )
2017
25
Function of inhibitor of Bruton's tyrosine kinase isoform I+ (IBTKI+) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response. ( 28710282 )
2017
26
Oral Supplementation of Glutamine Attenuates the Progression of Nonalcoholic Steatohepatitis in C57BL/6J Mice. ( 28931589 )
2017
27
Liver fibrosis in the context of nonalcoholic steatohepatitis: the role of adipokines. ( 28875689 )
2017
28
Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. ( 28878132 )
2017
29
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. ( 28875318 )
2017
30
The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial. ( 28892558 )
2017
31
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. ( 28912902 )
2017
32
Erratum: Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. ( 28845609 )
2017
33
Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. ( 28869588 )
2017
34
Caspase 3, 6, 8, and 9 Gene Expression in Peripheral Blood Leukocytes and Plasma Concentrations of IL-6 and TNF-I+ in Carriers of Different Polymorphic Marker -174G>C Genotypes of IL6 Gene Associated with the Risk of Nonalcoholic Steatohepatitis. ( 28091912 )
2017
35
Iron Overload in the Liver of 2 Children: Nonalcoholic Steatohepatitis and Juvenile Hemochromatosis. ( 28067690 )
2017
36
Treating Nonalcoholic Steatohepatitis (NASH) in Children: Not a Cinch Task. ( 28073147 )
2017
37
The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. ( 27922486 )
2017
38
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. ( 27797398 )
2017
39
Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. ( 28936971 )
2017
40
Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. ( 28941597 )
2017
41
Nonalcoholic steatohepatitis in children with severe obesity: A global concern. ( 28935179 )
2017
42
Glucose regulated protein 78 is potentially an important player in the development of nonalcoholic steatohepatitis. ( 28951310 )
2017
43
Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. ( 28079667 )
2017
44
Global Deletion of Glutathione S-Transferase A4 Exacerbates Developmental Nonalcoholic Steatohepatitis. ( 27998724 )
2017
45
Growth arrest and DNA damage-inducible 45I+ protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet. ( 28844958 )
2017
46
A Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis. ( 28051796 )
2017
47
Hepatic vagus nerve regulates Kupffer cell activation via I+7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis. ( 28044208 )
2017
48
Gd-EOB-DTPA-enhanced T1I8 imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits. ( 29278765 )
2017
49
Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats. ( 28886741 )
2017
50
Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. ( 29404480 )
2017

Variations for Nonalcoholic Steatohepatitis

Expression for Nonalcoholic Steatohepatitis

Search GEO for disease gene expression data for Nonalcoholic Steatohepatitis.

Pathways for Nonalcoholic Steatohepatitis

Pathways related to Nonalcoholic Steatohepatitis according to KEGG:

36
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 ADIPOQ IL6 INS LEP RETN TNF
2
Show member pathways
12.07 F2 IL6 INS TNF
4 11.77 IL6 LEP TNF
5
Show member pathways
11.71 IL6 INS PPARA TNF
6 11.68 IL6 INS SQSTM1
7
Show member pathways
11.62 ADIPOQ INS TNF
8 11.6 ADIPOQ IL6 INS LEP
9 11.35 ADIPOQ IL6 INS LEP PNPLA3 PPARA
10 11.3 ADIPOQ LEP PPARA TNF
11 10.8 IL6 TNF
12 10.7 GPT INS
13 10.6 ADIPOQ IL6 LEP TNF

GO Terms for Nonalcoholic Steatohepatitis

Cellular components related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 ADIPOQ F2 GPT HFE IL6 INS

Biological processes related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 glucose homeostasis GO:0042593 9.78 ADIPOQ INS LEP
2 positive regulation of MAPK cascade GO:0043410 9.75 IL6 INS LEP
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 ADIPOQ IL6 INS
4 response to insulin GO:0032868 9.7 LEP PPARA RETN
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 F2 INS LEP
6 response to glucocorticoid GO:0051384 9.67 ADIPOQ IL6 TNF
7 positive regulation of protein phosphorylation GO:0001934 9.67 ADIPOQ F2 SQSTM1 TNF
8 positive regulation of chemokine production GO:0032722 9.65 IL6 TNF
9 positive regulation of JAK-STAT cascade GO:0046427 9.65 IL6 LEP
10 negative regulation of lipid catabolic process GO:0050995 9.64 INS TNF
11 regulation of protein secretion GO:0050708 9.64 INS TNF
12 positive regulation of cellular protein metabolic process GO:0032270 9.63 ADIPOQ INS
13 positive regulation of long-term synaptic potentiation GO:1900273 9.63 INS SQSTM1
14 leukocyte tethering or rolling GO:0050901 9.62 LEP TNF
15 negative regulation of growth of symbiont in host GO:0044130 9.62 SQSTM1 TNF
16 glucose metabolic process GO:0006006 9.62 ADIPOQ INS LEP TNF
17 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.61 SQSTM1 TNF
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.61 IL6 RETN TNF
19 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.6 ADIPOQ PPARA
20 negative regulation of gluconeogenesis GO:0045721 9.59 ADIPOQ INS
21 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 INS LEP
22 negative regulation of fat cell differentiation GO:0045599 9.58 ADIPOQ IL6 TNF
23 negative regulation of glucose import GO:0046325 9.57 LEP TNF
24 negative regulation of appetite GO:0032099 9.55 LEP PPARA
25 positive regulation of peptide hormone secretion GO:0090277 9.54 HFE INS
26 regulation of receptor activity GO:0010469 9.5 ADIPOQ F2 IL6 INS LEP RETN
27 negative regulation of receptor binding GO:1900121 9.48 ADIPOQ HFE
28 negative regulation of feeding behavior GO:2000252 9.46 INS RETN
29 acute-phase response GO:0006953 9.46 F2 HFE IL6 INS
30 negative regulation of lipid storage GO:0010888 9.43 IL6 LEP TNF
31 positive regulation of STAT protein import into nucleus GO:2000366 8.8 F2 IL6 LEP

Molecular functions related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN

Sources for Nonalcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....